Using RNF43-mutant PAAD cells, Zachary et al. [16] discovered that anti-FZD5 and anti-FZD8 antibodies could repress the cancer cell growth, providing support for chemotherapeutics development in PAAD. The gene discussed is RNF43; the disease is pancreatic adenocarcinoma.